BioPharmSignal logoBioPharmSignal

Biotech News

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Black Diamond Therapeutics (BDTX)Black Diamond TherapeuticsEarnings

Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025 Exploring partnership opportunities to advance pivotal development of silevertinib in NSCLC and GBM Plan to meet with FDA

Related news

BDTXBlack Diamond Therapeutics2026-08-05 20:01 EST

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

KYMRKymera2026-08-05 11:00 EST

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

View all latest news

Black Diamond Therapeutics

Mutation-Family Precision Oncology Black Diamond Therapeutics develops MasterKey therapies designed to inhibit families of oncogenic mutations with a single small molecule. Silevertinib Silevertinib is a brain-penetrant kinase inhibitor targeting canonical and noncanonical EGFR mutations, including alterations that are difficult to...

Recent company news

BDTXBlack Diamond Therapeutics2026-08-05 20:01 EST

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-05-22 12:00 EST

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

BDTXBlack Diamond Therapeutics2026-05-21 21:14 EST

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

BDTXBlack Diamond Therapeutics2026-05-19 12:00 EST

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

BDTXBlack Diamond Therapeutics2026-05-07 11:30 EST

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
2.21 USD
Market cap
124.92M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States